Medical News

Cell Renewal Therapy is the result of more than 70 years of research, and developing cellular biotechnology, by BIOCELL ULTRAVITAL (BioPharma) in Switzerland, and by Biocell Laboratories in France. Each formula in their product line is formulated with 100% naturally occurring materials, clinically tested, that do not contain drugs, steroids , chemicals or other substances which would represent a risk to health.

BioPharma Cell Renewal Therapy is mainly a preventive therapeutic method, which provides fundamental nutrients through opotherapic (organ enhancing) embryo assets (derived from embryonic stem cells of healthy black sheep embryos), organic phyto-nutrients, enzymes, amino acids, potent antioxidants and other non-chemical substances of recognized therapeutic action, that stimulate cell revitalization and regeneration, strengthening the cell, its cycles and specific functions, in its stages of renewal and mitosis.

These 100% bio-compatible components are included in the BioCell formulas to enhance traditional organotherapy and cell therapy formulas of purely embryonic origin. The main objective is to revitalize healthy and / or damaged organs by optimizing the function of the tissues and reversal of possible destructive structural changes, especially those which are predisposed by individual hereditary factors.

What we know about cell biology and its behavior, is that our cells gradually, over time, lose the ability to function in the precise way they were intended and as they should.

BioPharma Cell Renewal Therapy has a medium and long term effect: stimulating the unique mechanisms of revitalization and healing possessed by the different cells and tissues. Its therapeutic action works by enabling the contents of each formula to be incorporated into the cells and accepted as their own. This is accomplished in a way that it can never act injuriously to the recipient organism; and thus, reversing or preventing deterioration and aging, and improving the quality of cells and tissues in various types of degenerative conditions.

BioPharma products are categorized as “Cellular Nano Nutrition”, which takes into account that all tissues have a structure that depends on the cooperation between and amongst the different types of cells. Therefore, it is fundamental to the health of tissues and organs, that the cells that constitute them are healthy, in order for them to perform their functions adequately.

Cellular nutrition, for therapeutic cell renewal purposes, is then defined as: “the supply of nutrients, through formulas that the cells of the body need, in order to obtain energy, and maintain their structure and functions.”

The cell is wrapped in a thin membrane composed mainly of fatty material, and within it are protein molecules that perform specialized functions. The cellular membrane exerts a vital function, since it controls what can or cannot happen to the cellular interior.

The cellular interior is divided into compartments, among which is the nucleus. Inside the nucleus is the genetic material that carries all the information necessary for the structure and functioning of the cell and, by extension, the organ it comprises.

The cell’s functioning and structure are affected by both a deficiency of minerals and vitamins and by an excess of substances such as toxins, as well as sodium, calcium and sugar. Nutrient deficiency slows down cellular functions and depletes energy in the cell. An excess of toxins inhibits or destroys the enzymes, hinders the production of cellular energy, and incapacitates the cell’s ability to synthesize proteins.

Some toxins affect the genetic material, and others can damage the cell wall. As an example, excess sodium and sugar, while “nutrients”, in excess can also have a toxic character, and affect the cell in the same way other toxins do.

How Cell Renewal Therapy Works

BioPharma’s Cell Renewal Therapy, through its exclusive formulas, allows us to transform those organs that are sick or in the process of aging, into healthy, physiologically younger organs, with greater functional capacity. Their components – derived from embryonic stem cells and other biocompatible ingredients described earlier -- are activators of a series of stimuli that the cells need for their normal cycle of continuous renewal. These can now be effectively incorporated into the body orally (as well as by intra muscular injection).

Once into the bloodstream, these various components are assimilated by the organism’s specifically targeted tissues and cells through “endocytosis” (a process of cellular ingestion by which the plasma membrane of the cells folds inwards to bring substances into the cell), introducing the beneficial ingredients into the cells. This mechanism brings about many stimulating biochemical changes, and begins the nutritional cycle of effective CELLULAR RENEWAL.

Thus, the formulas specific for organs such as the heart, thyroid and central nervous system, etc., can bring about a higher state of health through improved function and structure at the cellular level.

Each BioPharma Cell Renewal Therapy Formula, brings with it fresh genetic information contained in its DNA and RNA (from highly potent embryonic stem cells), stimulating secretions that activate old or diseased cells in order to reprogram them to function properly, providing the beneficiary organisms with a large number of biochemical substrates and enzymes, which contains the information necessary to revitalize an organ or a gland.

BioPharma Cell Renewal Therapy formulas contains several compounds that are mainly responsible for properly nourishing the cells, as well as embryonic cells and tissues that increase positive changes in the cell cycle, assisting in transforming the dysfunctional aspects seen in aging or prematurely deteriorating cells.

Through the endocytosis process, the different components are first incorporated as essential nutrients, while the embryonic tissues reach the organ that is suffering with low vitality and that needs to be energized.

This beneficial action of the Cellular Renewal process is usually perceived within 6 - 12 weeks, as the improvement expand slowly from individual cells to the tissues, from the tissue to the organ and from the organ to the system. Older and less compensated patients will take longer to see benefits, as more of their original cells have been affected and diminished in function, or depleted.

Some specialists feel that the most important result, when using BioPharma’s Cell Renewal Therapy, is the revitalization of the body’s natural defense mechanisms, which is greatly assisted by the inclusion of Thymus/Spleen extracts to help potentiate the immune system. When damage occurs to the cells that make up the different tissues and organs involved in the immune system, either by aging or by environmental poisoning, the body becomes defenseless both to external invasion and to internal degeneration.

The damage caused to the organs of the immune system can be reversed by stimulating the body's defense mechanisms in order to invigorate the health of the weakened organ, greatly assisted by the Thymus and Spleen extracts present in most of the Biocell Ultravital products.

[Derived and edited from the works of Francisco Llano, MD and used with his permission.]

DISCLAIMER Nothing in this article has been approved by the FDA or other governmental agency and are strictly the opinions of the authors based on their clinical observations, expressed per the 1st Amendment of the Bill of Rights of the United States Constitution. No one should engage in any new form of nutritional or other potentially health enhancing activity without the supervision of a qualified health care professional.

New studies reveal that nearly 1 billion people worldwide, are likely to have vitamin D deficiency or insufficiency as a result of chronic disease and inadequate sun exposure.

A number of previous studies suggest that low plasma levels of vitamin D3 (measured as 25-hydroxyvitamin D, 25[OH]D) associate with high arterial blood pressure and hypertension (high blood pressure) risk. Elina Hypponen, from the University of South Australia (Australia), and colleagues completed a Mendelian randomization study using genetic data from the D-CarDia collaboration involving more than 146,500 men and women of European ancestry. The team used two common genetic variants that affect circulating plasma vitamin D concentrations to measure whether there was a causal effect between vitamin D status and blood pressure. For each 10% increase in plasma vitamin D, the researchers observed a drop in both diastolic and systolic blood pressures, as well as an 8.1% decreased risk of developing hypertension. The study authors conclude that: “Increased plasma concentrations of 25(OH)D might reduce the risk of hypertension."

Many studies agree that Daily supplementation of Vitamin D may reduce the risk of heart failure, among older men and women.

Previous studies have linked low blood levels of Vitamin D with an increased risk for cardiovascular disorders and diseases. JA Ford, from the University of Aberdeen (United Kingdom), and colleagues analyzed data collected in the Randomized Evaluation of Calcium or Vitamin D (RECORD) clinical study, and also completed a meta-analysis of other studies of Vitamin D supplementation. RECORD enrolled 5./292 subjects, randomized to receive 800 IU/day of Vitamin D3; 1,000 mg/day of calcium; vitamin D and calcium; or placebo. Following the subjects for 3 years, the data revealed that the risk of heart failure was reduced by 25% for the vitamin D groups, as compared to the groups taking no supplemental vitamin D. The meta-analysis involved 21 selected studies totaling 13,033 subjects, median age of 60 years. It found that the risk of heart failure was reduced by 18% for subjects taking a daily Vitamin D supplement, as compared to placebo. The study authors write that: “Vitamin D supplementation might protect against cardiac failure in older people.”

Cell Renewal Therapies are mainly preventive and / or coadjuvant therapeutic methods, that provides freeze-dried embryonic extracts and other key nutrients such as vitamins, phyto-organic amino acids, enzymes, and potent antioxidants to neutralize the action of free radicals that stimulate revitalization and cell regeneration, strengthening the nucleus of the cell, its cycles and specific functions in its stage of renewal and subsequent mitosis.

One of Biocell´s featured products is BIOENZYM, it contains the vitamin D3 that the body needs to prevent chronic and degenerative diseases, it also contains anti-inflammatory enzymes , that will also help in the prevention of heart problems, and other degenerative diseases liked with inflammation.

Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M; for the RECORD Trial Group. “Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis.” Am J Clin Nutr. 2014 Jul 23. pii: ajcn.082602.

Karani S Vimaleswaran, Alana Cavadino, Diane J Berry, Elina Hypponen, LifeLines Cohort Study investigators, et al. “Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study.” The Lancet Diabetes & Endocrinology, June 26, 2014.

Human-Ultracell V, has incorporated enzymes to its extraordinary biological combination of cellular extracts and hormonal inducers with the aim of filling all the spaces that lead to a tissue regeneration and a complete systematic renewal. The enzymatic component is the link that binds all organic compounds, acting as a biocatalyst.

Enzymes make innumerable metabolic processes possible. Among the many enzymes involved in metabolism, there is a special class called regulatory enzymes, which can sense various metabolic signals and change their catalytic velocity. Through its action the enzymatic systems used in the Human-Ultracell V formula are highly coordinated to establish a harmonious inter-relationship between the many different metabolic activities that are necessary to sustain the state of life. The professionals assigned to Biocell have studied for more than 15 years, the performance in inflammatory processes, especially in arthralgia and edema of various etiologies. These investigations confirmed that the application of systematic enzymotherapy is multiple. The result of all these long years of study led Biocell to decide the incorporation of enzymatic systems to the Human-Ultracell V formula, where they will exert a catalytic as well as synergic function that sets in motion the mechanism of systematic revitalization and therefore the integral rejuvenation of the organism.

One of the most important enzymes in the Human-Ultracell V, is the Glutathione reductase (GR), also known as glutathione-disulfide reductase (GSR) is an enzyme that in humans is encoded by the GSR gene. Glutathione reductase, catalyzes the reduction of glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH), which is a critical molecule in resisting oxidative stress and maintaining the reducing environment of the cell.

Glutathione plays a key role in maintaining proper function and preventing oxidative stress in human cells. It can act as a scavenger for hydroxyl radicals, singlet oxygen, and various electrophiles. Reduced glutathione reduces the oxidized form of the enzyme glutathione peroxidase, which in turn reduces hydrogen peroxide (H2O2), a dangerously reactive species within the cell. In addition, it plays a key role in the metabolism and clearance of xenobiotics, acts as a cofactor in certain detoxifying enzymes, participates in transport, and regenerates antioxidants such and Vitamins E and C to their reactive forms. The ratio of GSSG/GSH present in the cell is a key factor in properly maintaining the oxidative balance of the cell, that is, it is critical that the cell maintains high levels of the reduced glutathione and a low level of the oxidized Glutathione disulfide. This narrow balance is maintained by glutathione reductase, which catalyzes the reduction of GSSG to GSH.

The battle worth fighting.

The first drug to treat low sexual desire in women has received US Food and Drug Administration (FDA) approval.

But the little pink tablets, to be sold under the brand name Addyi, have proven controversial. Here is what you need to know about what has been dubbed the "female Viagra".

Er, it shouldn't really be called 'female Viagra'

That flibanserin - to use its chemical name - would draw comparison to its blockbuster male equivalent was inevitable but the nickname is misleading.

While a Viagra pill treats erectile dysfunction by improving blood flow to the penis, flibanserin was developed as an anti-depressant and boosts sexual desire by balancing chemicals in the brain.

Specifically, the drug treats hypoactive sexual desire disorder (HSDD), essentially a lack of libido that causes distress and is thought to affect between 5.5 million and 8.6 million US women.

By gaining approval, Addyi's makers Sprout succeeded where medical giants have failed.

Pfizer, Procter & Gamble and others have all tried to develop products treating low sexual desire in women.

While the product has its pros and cons, medical practitioners now have a new treatment available to treat a common condition.

Sprout plans to launch the product in mid-October. A rival, Palatin Technologies, has an alternative treatment for HSDD in late-stage trials.

Addyi has minimal effects, but potentially severe side-effects

Women taking the drug reported around one more sexually satisfying event a month, compared to a placebo.

But supporters say even this small benefit is worthwhile - "I want to want my husband, it is that simple,'' said Amanda Parrish, one of the women involved in trials.

The FDA's approval of Addyi comes with tough safety measures, meaning that its usage is unlikely to be as widespread as with male Viagra.

Doctors will only be able to prescribe the drug after counselling patients about potential side-effects, including low blood pressure, nausea and fainting.

Pharmacists must remind patients not to drink alcohol while taking the drug, which can make the effects more severe.

And while Viagra can be taken shortly before having sex, Addyi must be taken daily.

It is a victory for campaigners

"This is the biggest breakthrough in women's sexual health since the advent of 'the Pill' for contraception," The National Consumers League said in a statement.

Lobbying group Even the Score, which has campaigned for better treatment of women's sexual health, accused the FDA of gender bias, highlighting the numerous products available treating sexual dysfunction in men, although none of them treat low desire.

Some physicians have welcomed the approval too, such as Dr Lauren Streicher, associate professor of clinical obstetrics and gynaecology at Northwestern University.

"This is an enormous, enormous advance in women's health.

"Of all the sexual dysfunctions, this is by far the most common in every single age category and we've had no options for women up until now."

But sceptics remain

Addyi's critics argue that the FDA has approved a drug of marginal impact with potentially serious side-effects. Previous versions of the drug have been rejected by the FDA.

"Unfortunately, we haven't heard the last of this drug," warned consumer group Public Citizen.

PharmedOut, which focuses on marketing in pharmaceuticals, said the FDA has been swayed by "a clever, aggressive public relations campaign".

"This opens the way for drug companies to pressure the FDA through public relations campaigns to approve more bad drugs: It's bad news for rational drug approval," Adriane Fugh-Berman, a pharmacology professor and director of PharmedOut told the Washington Post.

The medical status of HSDD has been disputed, with some arguing that low libido in women cannot be treated in the same way as erectile dysfunction in men.

"Women's sexuality is very complicated. It's not a matter of just taking that pill, by the way, and then all of a sudden the lights go on," Judy Kuriansky, a clinical psychologist and certified sex therapist, told CNN.

 

 

The number of people living with diabetes has soared by nearly 60% in the past decade, Diabetes UK warns.

The charity said more than 3.3 million people have some form of the condition, up from 2.1 million in 2005.

The inability to control the level of sugar in the blood can lead to blindness and amputations and is a massive drain on NHS resources.

The NHS said it was time to tackle poor lifestyle, which is a major factor behind the rise.

Diabetes UK called for the NHS to improve care for patients and for greater efforts to prevent diabetes.

Roughly 90% of cases are type 2 diabetes, which is the form closely linked to diet and obesity.

People with type 1 generally develop it in childhood and are unable to produce the hormone insulin to control their blood sugar levels.

New diagnosis

Dr Joan St John, a GP in Brent in north-west London, where diabetes levels are some of the highest in the country, said the condition had become incredibly widespread.

She told the BBC News website: "It's very noticeable in that not a week goes by that you don't make a new diagnosis of diabetes, at least one if not two or three; previously that might have been one a month."

The complications of uncontrolled blood sugar levels can be severe, including nerve damage, loss of vision and organ damage.

The condition even leads to 135 foot amputations every week across the country.

Dr St John added: "Unfortunately that historical myth that it is not a serious condition is still retained by some people and you have to dispel that myth."

"One of the most miserable complications is neuropathy [nerve damage] which can cause a constant nagging, gnawing ache, usually in the legs or feet, and this can be really disturbing and there is no cure for it," she added.

Data published last week showed that diabetes medication now accounts for 10% of the NHS drugs bill.

Nearly £869m was spent on drugs, including insulin and metformin, marking a sharp rise from the £514m being spent a decade ago, when the drugs accounted for just 6.6% of the prescriptions budget.

Part of GP pay is linked to diagnosing and treating diabetes - and has been for years. The government says this is to improve care.

The reasons why levels of type 1 diabetes are increasing are not understood.

However, the explanation for the soaring cases of type 2 are being placed squarely on the nation's ballooning waistline.

Barbara Young, the chief executive of Diabetes UK, said the government needed to act to prevent new cases and improve treatment for those already affected.

She said: "Diabetes already costs the NHS nearly £10bn a year, and 80% of this is spent on managing avoidable complications."

"So there is huge potential to save money and reduce pressure on NHS hospitals and services through providing better care to prevent people with diabetes from developing devastating and costly complications," she added.

Dr Martin McShane, NHS England's Director for Long Term Conditions, said: "These figures are a stark warning and reveal the increasing cost of diabetes.

"We've said it before and we'll say it again, it's time to get serious about lifestyle change."

 

Depression runs deep. So deep, in fact, that researchers now say the individual cells of a person with severe depression age faster than usual.

A team of researchers in the Netherlands wanted to know why people with depression are at greater risk for diseases related to aging: diabetes, obesity, cancer and heart disease. So they looked at three groups of people: 1,100 currently experiencing major depressive disorder (MDD), 800 who had MDD in the past, and 500 people who reported no signs of depression.

The researchers checked out each person’s telomeres—the protective caps on the end of their chromosomes that wear down over time. The length of a person’s telomeres is a key measure of cellular aging.

Early Aging

People with MDD had much shorter telomeres than those who didn’t. That held true whether the depression was in the present or the past. Plus, the longer the duration of depression, or the more severe its symptoms, the shorter a person’s telomeres were. (To be sure of the association, researchers took into account factors like smoking, drinking and other lifestyle differences.)

Does depression accelerate aging? It’s too early to say. The findings, published yesterday in Molecular Psychiatry, show a connection between depression and cellular aging, but not a causal relationship. And the research was limited to severe depression, excluding milder and perhaps more common forms.

The good news is that previous research suggests cellular aging can be reversed with diet and exercise. Yet another reason to strap on your sneakers.

Older women who have high levels of serum glucose are at increased risk for colorectal cancer, a longitudinal study found.

Compared with postmenopausal women whose glucose levels were in the lowest tertile, those in the highest tertile had a multivariable adjusted hazard ratio for colorectal cancer of 1.74 (95% CI 0.97 to 3.15, P for trend=0.06), according to Geoffrey C. Kabat, MD, of Albert Einstein College of Medicine in New York, and colleagues.

And the risk was even higher when the analysis was specifically for colon cancer (HR 2.25, 95% CI 1.12 to 4.51, P for trend=0.02), they reported online in the British Journal of Cancer.

Although obesity and related conditions such as diabetes and the metabolic syndrome have been linked with colorectal cancer, it has not been known whether the risk relates to levels of circulating insulin or glucose.

Insulin theoretically could contribute in that it is anti-apoptotic and mitogenic, whereas glucose might increase the risk by providing an energy source for malignant cells, the researchers explained.

But the results of epidemiologic studies looking at a possible link between insulin and glucose levels have had inconsistent findings, possibly because of differences in types of study as well as in populations and risk factors.

So to examine this prospectively, Kabat and colleagues analyzed data from a subset of women participating in the Women's Health Initiative who had baseline and serial follow-up measurements of fasting serum glucose and insulin.

Covariates in the analysis included age, body mass index (BMI), alcohol consumption, physical activity, ethnicity, and family history of colorectal cancer.

During a median of 11.9 years, there were 81 cases of colorectal cancer among the cohort of 4,902 women.

A total of 65 of the cases were colon cancer, in six the malignancy was the rectosigmoid junction, and in 10 the cancer was rectal.

Compared with women who did not develop colorectal cancer, those who did were older by about two years, were more often white, and were less likely to be physically active.

Unlike glucose, which had a "robust" association, baseline levels of insulin and the insulin resistance index were not associated with an increased risk of colorectal or colon cancer, according to the researchers.

After mutual adjustment for glucose and insulin, the hazard ratio for the highest tertile of glucose versus the lowest was 1.72 (95% CI 0.94 to 3.15, P for trend=0.07), while the hazard ratio for insulin was 0.88 (95% CI 0.47 to 1.65, P for trend=0.70).

The hazard ratio for each 1 mg/dL⁻¹ of glucose was 1.031 (95% CI 1.009 to 1.054, P for trend=0.0066).

The risk for both colorectal and colon cancer with higher levels of glucose was seen in patients whose BMI was 27.76 or higher, with a hazard ratio per mg/dL⁻¹ of 1.029 (95% CI 0.997 to 1.062, P=0.08), and also for those whose BMI was lower (HR 1.031, 95% CI 1.001 to 1.063, P=0.04).

Here, too, the baseline insulin and the insulin resistance index were not associated with cancer risk.

The researchers also did the analysis excluding patients whose cancer developed within two years of study entry to eliminate possible cases of subclinical disease, and found similar results, with a hazard ratio for the highest versus lowest tertile of glucose of 1.81 (95% CI 0.93 to 3.51, P for trend 0.07).

"In conclusion," the researchers wrote, "in this cohort study of postmenopausal women, elevated fasting serum glucose, but not insulin or [the homeostasis model assessment of insulin resistance] was associated with roughly a twofold increased risk of colorectal cancer."

A limitation of the study was the small number of cancer cases identified and the researchers' resulting inability to more thoroughly analyze subsets of cases according to cancer sites and variables.

Choline is an essential nutrient that is utilized by the body to manufacture neurotransmitters and cell membrane constituents.  Choline is found in green leafy vegetables, fish, peanuts, organ meat, soybeans, yeast, wheat germ, and lecithin.  Rhoda Au, from Boston University School of Medicine (Massachusetts, USA), and colleagues analyzed population data from the Framingham study, involving 1400 adults, ages 36 to 83 years, who completed a food survey and then underwent tests of memory and other cognitive abilities, including MRI brain imaging. The subjects who reported high choline intake performed better on the memory tasks, as compared to those reporting lower intake. Additionally, the researchers found that study participants with higher choline intake were less likely to show areas of white matter hyperintensity – an indicator of blood vessel disease in the brain. The study authors conclude that: “In this community-based population …  higher concurrent choline intake was related to better cognitive performance.”

Read more

Statistics released today by the American Society of Plastic Surgeons (ASPS) show that more men are going under the knife. Overall cosmetic plastic surgery procedures in men were up 2 percent in 2010 compared to 2009. However, many male surgical procedures increased significantly. Facelifts for men rose 14 percent in 2010 while male liposuction increased 7 percent.

2010 ASPS statistics show that men underwent more than 1.1 million cosmetic procedures, both minimally-invasive and surgical. The majority of the the Men's Top 10 fastest-growing cosmetic procedures are surgical, which bucks the previous trend of growth in minimally-invasive treatments.

"The growth in cosmetic surgical procedures for men may be a product of our aging baby boomers who are now ready to have plastic surgery," said ASPS President Phillip Haeck, MD. "Minimally-invasive procedures such as Botox® and soft tissue fillers work to a point. However, as you age and gravity takes over, surgical procedures that lift the skin are necessary in order to show significant improvement."

Men's Top Ten: Fastest-Growing Male Cosmetic Procedures (by percentage increase)

The list is comprised of the fastest-growing surgical and minimally-invasive procedures from 2009 to 2010. Criteria for inclusion: Procedure performed on at least 1,000 men in 2010. (Surgical procedures are denoted by *).

1) Facelift* - 14% Increase
2) Ear Surgery* (Otoplasty) - 11% Increase
3) Soft Tissue Fillers - 10% Increase
4) Botulinum Toxin Type A - 9% Increase
5) Liposuction* - 7% Increase
6) Breast Reduction in Men* - 6% Increase
7) Eyelid Surgery* - 4% Increase
8) Dermabrasion* - 4% Increase
9) Laser Hair Removal - 4% Increase
10) Laser Treatment of Leg Veins - 4% Increase

Plastic surgeons say that another trend they see in male plastic surgery is the type of patient seeking their services.

"Typically people think of celebrities and high profile men going under the knife," said Stephen Baker, MD, an ASPS Member Surgeon based in Washington DC. "And while that may be true, the typical male cosmetic surgery patient that I see is an average guy who wants to look as good as he feels. Most of my patients are 'men's men,' the kind of guy you might not think would have plastic surgery."

Dr. Baker said that baby boomers who are now reaching retirement age are the new face of the male plastic surgery trend. "They want to look good. So when they have the financial means to do it, they are ready to do it now," said Dr. Baker.

In fact, one of Dr. Baker's patients is an "average Joe" named Joe Marek. Joe recently underwent a facelift and eyelid surgery. The 57-year old said, "I didn't feel that old. I felt young. I was working out. I was pretty active and I wanted to look like I felt inside."

Joe also said his 52-year-old girlfriend supported his decision to have plastic surgery.

Men's Top Ten: Most Popular Male Cosmetic Procedures (by volume)

This list is comprised of the top five surgical and top five minimally-invasive procedures by volume in 2010:

2010 Top Five Male Cosmetic Surgical Procedures:

1) Nose Reshaping (64,000)
2) Eyelid Surgery (31,000)
3) Liposuction (24,000)
4) Breast Reduction in Men (18,000)
5) Hair Transplantation (13,000)

2010 Top Five Male Cosmetic Minimally-Invasive Procedures:
1) Botulinum Toxin Type A (337,000)
2) Laser Hair Removal (165,000)
3) Microdermabrasion (158,000)
4) Chemical Peel (90,000)
5) Soft Tissue Fillers (78,000)

For more statistics released today on trends in plastic surgery including gender, age, regional, national average fees, and other breakouts, visit the ASPS Report of the 2010 Plastic Surgery Statistics here. (Stats on this site will be updated with the specific demographics and trends when embargo lifts on 3/21/11). Visitors can also find information about procedures and referrals to ASPS Member Surgeons.

Source:
American Society of Plastic Surgeons (ASPS)